The challenges of innovative therapeutic interventions in hemophilia
Louis M. Aledort
An update on UCL/St Jude Haemophilia studies; successes and obstacles ahead
Acquired TTP: are we ready for a prognosis-dependent management?
Hemolytic uremic syndrome (HUS)
The most recent advances in aHUS and TTP including complement and VWFcomplement interactions.
Giuseppe Remuzzi, Marina Noris
Randomisation or real world data?
Frits R. Rosendaal, Leiden, The Netherlands
Von Willebrand factor
Collagen and VWF interactions and beyond
Veronica Flood, Robert R. Montgomery
The genetics of von Willebrand disease, to include recent developments from ourselves and others.
Anne C. Goodeve
The potential use of nanobodies in the treatment of VWD and hemophilia
Peter J. Lenting
Determinants of FVIII inhibitor risk: Is VWF a key factor?
David P. Lillicrap
VWF regulation of blood vessel formation and function
Anna M. Randi
Old concepts and new functions of von Willebrand factor: 2017
Zaverio M. Ruggeri
Emerging concepts in acquired thrombotic thrombocytopenic purpura
Endocytosis of factor FVIII by antigen-presenting cells: roles of von Willebrand factor and complement
Sebastien Lacroix-Desmazes, Paris, France
Differential diagnosis of thrombotic microangiopathies
Jeffrey C. Laurence, New York, USA
Immune recognition of ADAMTS13 in acquired TTP
Jan Voorberg, Amsterdam, The Netherlands
Mechanism of thrombotic microangiopathy: lesson from zebrafish to men
X. Long Zheng, Birmingham, USA
… more preliminary topics soon on line, stay tuned!